BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 915 filers reported holding BAXTER INTL INC in Q4 2013. The put-call ratio across all filers is 0.90 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $149,040,000 | -1.1% | 3,361,295 | +6.1% | 0.17% | -6.5% |
| Q3 2016 | $150,730,000 | -1.3% | 3,166,596 | -6.3% | 0.18% | -4.1% |
| Q2 2016 | $152,755,000 | +15.9% | 3,378,041 | +5.3% | 0.19% | +12.9% |
| Q1 2016 | $131,745,000 | +43.7% | 3,207,045 | +33.5% | 0.17% | +46.2% |
| Q4 2015 | $91,659,000 | +26.8% | 2,402,604 | +9.2% | 0.12% | +19.4% |
| Q3 2015 | $72,289,000 | -57.5% | 2,200,593 | -9.4% | 0.10% | -53.6% |
| Q2 2015 | $169,901,000 | +15.3% | 2,429,583 | +12.9% | 0.21% | +9.3% |
| Q1 2015 | $147,383,000 | -0.2% | 2,151,576 | +6.8% | 0.19% | -1.5% |
| Q4 2014 | $147,688,000 | +12.8% | 2,015,119 | +10.5% | 0.20% | +7.1% |
| Q3 2014 | $130,909,000 | +10.4% | 1,824,005 | +11.3% | 0.18% | +15.1% |
| Q2 2014 | $118,538,000 | +21.9% | 1,639,532 | +24.0% | 0.16% | +12.8% |
| Q1 2014 | $97,253,000 | +21.8% | 1,321,726 | +15.2% | 0.14% | +19.5% |
| Q4 2013 | $79,832,000 | +14.3% | 1,147,829 | +8.0% | 0.12% | +2.6% |
| Q3 2013 | $69,846,000 | +6.5% | 1,063,273 | +12.3% | 0.12% | -1.7% |
| Q2 2013 | $65,574,000 | – | 946,646 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |